retatrutide clinical trial south korea Eli Lilly's next-generation obesity treatment "retatrutide" has ignited competition for next-generat Phase 2 Trial of Retatrutide

Many trial participants reported noticeable reductions in hunger and food intake during this phase, with weight loss varying by dose and titration

Besides the acute phase gastrointestinal effects which may lead to up to 10% of people discontinuing the drugs, there are other potential GI side effects of obstruction, excessive loss of muscle mass, and potentially association with some eye disease adverse events

However, sustainable clinical weight loss is a steady progression, with most individuals seeing measurable and significant changes in scale weight and body composition within 4 to 12 weeks of consistent treatment

[DOI] [PMC free article] [PubMed] [Google Scholar] 57.Ma X., Liu Z., Ilyas I., Little P.J., Kamato D., Sahebka A., Chen Z., Luo S., Zheng X., Weng J., et al

With GLP 1 medications, meaningful results happen week by week as appetite, metabolism, and cravings shift naturally

The Role of Genetic Context in Precision GLP-1 Selection Genetic variants in GLP-1R, GIPR, MC4R, and FTO genes may influence metabolic response and medication sensitivity